Mikkel Malham

Dr. Mikkel Malham

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MMMikkel Malham
Mikkel Malham
SJSøren Peter Jørgensen
Søren Peter Jørgensen
POPeter Ott
Peter Ott
JAJørgen Agnholt
Jørgen Agnholt
HVHendrik Vilstrup
Hendrik Vilstrup
JDJens F Dahlerup
Jens F Dahlerup
To examine the vitamin D status in patients with alcoholic cirrhosis compared to those with primary biliary cirrhosis. Our retrospective case series comprised 89 patients with alcoholic cirrhosis and 34 patients with primary biliary cirrhosis who visited our outpatient clinic in 2005 and underwent a serum vitamin D status assessment. Among the patients with alcoholic cirrhosis, 85% had serum vitamin D levels below 50 nmol/L and 55% had levels below 25 nmol/L, as compared to 60% and 16% of the patients with primary biliary cirrhosis, respectively (P < 0.001). In both groups, serum vitamin D levels decreased with increasing liver disease severity, as determined by the Child-Pugh score. Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology, with lower levels of vitamin D in alcoholic cirrhosis than in primary biliary cirrhosis.

Verified
Journal Article
Open access
PDF file
JJJaslin James
Jaslin James
LRLene Riis
Lene Riis
MMMikkel Malham
Mikkel Malham
Estrid HøgdallEstrid Høgdall
Estrid Høgdall
ELEbbe Langholz
Ebbe Langholz
BNBoye Schnack Nielsen
Boye Schnack Nielsen
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). These are chronic autoimmune diseases of unknown etiology affecting the gastrointestinal tract. The IBD population includes a heterogeneous group of patients with varying disease courses requiring personalized treatment protocols. The complexity of the disease often delays the diagnosis and the initiation of appropriate treatments. In a subset of patients, IBD leads to colitis-associated cancer (CAC). MicroRNAs are single-stranded regulatory noncoding RNAs of 18 to 22 nucleotides with putative roles in the pathogenesis of IBD and colorectal cancer. They have been explored as biomarkers and therapeutic targets. Both tissue-derived and circulating microRNAs have emerged as promising biomarkers in the differential diagnosis and in the prognosis of disease severity of IBD as well as predictive biomarkers in drug resistance. In addition, knowledge of the cellular localization of differentially expressed microRNAs is a prerequisite for deciphering the biological role of these important epigenetic regulators and the cellular localization may even contribute to an alternative repertoire of biomarkers. In this review, we discuss findings based on RT-qPCR, microarray profiling, next generation sequencing and in situ hybridization of microRNA biomarkers identified in the circulation and in tissue biopsies.

8 May 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MMMikkel Malham
Mikkel Malham
CJChristian Jakobsen
Christian Jakobsen
APAnders Paerregaard
Anders Paerregaard
LVLauri J. Virta
Lauri J. Virta
KKKaija-Leena Kolho
Kaija-Leena Kolho
VWVibeke Wewer
Vibeke Wewer
Summary: Background: Recent studies report increased risks of both cancer and mortality in paediatric onset inflammatory bowel disease (pIBD) but the reproducibility of this is unknown.Aim: To estimate the risk of cancer and mortality in the Danish and Finnish pIBD population in a 23‐year period compared to the general population.Methods: The pIBD population was defined as individuals registered in the national patient registries with a diagnosis of Crohn's disease (CD), ulcerative colitis (UC) or IBD‐unclassified before their 18th birthday from 1992 to 2014. This cohort was cross referenced with the national cancer and mortality registries identifying all pIBD patients who subsequently developed cancer and/ or died and followed up to the end of 2014. Risk estimates are presented as standardised incidence ratios calculated based on incidence figures from the populations.Results: Six thousand six hundred and eight‐nine patients with pIBD were identified (median age at follow‐up 22.3 years; median follow‐up: 9.6 years [interquartile range: 4.8‐16.0]). Seventy‐two subsequently developed cancer and 65 died. The standardised incidence ratio of cancer in general was 2.6 (95% CI: 1.8‐3.7) and 2.5 (95% CI: 1.8‐3.4) in CD and UC, respectively. The standardised mortality ratios were 2.2 (95% CI: 1.4‐3.4) and 3.7 (95% CI: 2.7‐5.0) in CD and UC, respectively. The leading causes for mortality were cancer, suicide and infections.Conclusions: We found an increased risk of cancer and mortality in pIBD. This underlines the importance of cancer surveillance programs and assessment of mental health in the standard of care in adolescent pIBD patients.

16 September 2019 in GastroHep
Verified
Journal Article
Open access
PDF file
MMMikkel Malham
Mikkel Malham
CJChristian Jakobsen
Christian Jakobsen
MVMarianne K. Vester‐Andersen
Marianne K. Vester‐Andersen
BLBobby Lo
Bobby Lo
APAnders Paerregaard
Anders Paerregaard
VWVibeke Wewer
Vibeke Wewer
Background Paediatric onset IBD (pIBD) has been reported to be more aggressive than adult onset IBD (aIBD). Yet, a more extensive disease presentation in paediatric onset ulcerative colitis (pUC) has been the only consistent finding. Aims In a population‐based study, we aimed to further elucidate the differences in disease course between pIBD and aIBD. Methods We compared a pIBD cohort (diagnosis<15 years of age) and an aIBD cohort (diagnosis≥18 years of age). Medical records were retrieved manually at last follow‐up, and clinical data concerning IBD phenotype and treatment were registered. Results We included 333 pIBD and 449 aIBD patients. Patients with pIBD more often presented with extensive disease localization than aIBD (24%/9% of pCD/aCD with L4 disease localization and 67%/24% of pUC/aUC with E3 disease extent). Of the patients with inflammatory disease at diagnosis, 34% and 16% of pCD and aCD patients, respectively, progressed to complicated disease over the first seven years after diagnosis (P=0.002)). Patients with pUC were more often treated with systemic corticosteroids (HR 2.0 (CI: 1.6‐2.6), P<0.0001) and/or thiopurines (HR: 3.8(CI: 2.8‐5.2), p<0.0001). Lastly, pIBD patients more often received biologics (HR 2.5 (CI: 1.8‐3.6, P<0.0001) in CD and HR: 3.8 (CI: 2.1‐6.9, P<0.0001) in UC) and had an increased risk of relapse (incidence rate ratio of 1.8 (CI: 1.4‐2.2, P<0.0001)). Conclusions In this population‐based cohort study we demonstrated a more severe disease course in pIBD than in aIBD. This message should be considered by both paediatric and adult gastroenterologists when caring for pIBD patients.

19 September 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
MDMaria Dorn-Rasmussen
Maria Dorn-Rasmussen
BLBobby Lo
Bobby Lo
MZMirabella Zhao
Mirabella Zhao
GKGilaad G Kaplan
Gilaad G Kaplan
MMMikkel Malham
Mikkel Malham
JBJohan Burisch
Johan Burisch
Background: Incidence rates of inflammatory bowel disease [IBD] reported from developed countries are rising, with some levelling out. The aim of this study was to assess the disease burden of IBD by estimating the incidence and prevalence across age groups and projecting these to 2030 in a high-incidence country.Methods: Using an algorithm [incorporating ICD codes, medications and histopathology], patients [n = 69 862] diagnosed with Crohn’s disease [CD] or ulcerative colitis [UC] between 1980 and 2017 were identified in the Danish National Patient Registry and included in a nationwide cohort.Results: From 1980 to 2017 the overall incidence of CD increased from 5.1 [95% CI: 4.5–5.8] to 15.6 [95% CI: 14.6–16.6] per 100 000, while the incidence of UC increased from 6.2 [95% CI: 5.5–6.9] to 27.2 [95% CI: 25.9–28.6] per 100 000. For paediatric-onset CD [pCD], the incidence increased from 1.9 [95% CI: 1.2–2.8] to 9.9 [95% CI: 8.1–11.8] per 100 000 and from 1.8 [95% CI: 1.2–2.8] to 8.7 [95% CI: 7.1– 10.5] per 100 000 for paediatric-onset UC [pUC]. In 2017, the prevalence of CD and UC was 293 [95% CI: 288–297] and 523 [95% CI: 517–528] per 100 000. For pCD and pUC, the prevalence was 35 [95% CI: 31–38] and 28 [95% CI: 26–32] per 100 000.Conclusions: The incidence of paediatric- and adult-onset IBD in Denmark continues to increase and is among the highest in the world.

22 July 2019 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
MMMikkel Malham
Mikkel Malham
BLBerit Lilje
Berit Lilje
GHGunnar Houen
Gunnar Houen
KWKatrine Winther
Katrine Winther
PAPaal S. Andersen
Paal S. Andersen
CJChristian Jakobsen
Christian Jakobsen
Objectives: A microbiotic profile characterized by decreased abundance and richness has been described in inflammatory bowel disease (IBD). Recently, sequencing the microbiome to the species level has become possible, which can improve our understanding of the gut to host interaction in IBD. We aimed to describe the microbiotic profile in paediatric IBD and compare it to disease phenotype and disease course. Methods: Faecal samples were collected from a cross-sectional cohort. The microbiome analysis was performed using 16S and 18S rRNA sequencing with the miSeq instrument. Inflammatory activity was assessed by faecal calprotectin. Data regarding medical treatment and surgery in the year after faecal sampling were collected from patient charts. Results: One hundred and forty-three (143) paediatric IBD patients and 34 healthy controls (HC) were included. We found a reduced richness in IBD patients compared to HCs (controls vs. ulcerative colitis (UC), p < .001 and controls vs. Crohn’s disease (CD), p = .04)). Moreover, a high degree of intestinal inflammation and extensive disease extent was associated with reduced richness in UC (p = .02 and p = .04, respectively). Nine species were significantly associated with a healthy microbiome and three species were associated with IBD. Lastly, we found that the composition of the microbiome could distinguish between CD, UC and HCs. Conclusions: In this study, we found that the microbiome could discriminate between IBD phenotypes and predict which patients were at risk of surgery. In the future, this could be included as part of the diagnostic work-up in IBD patients.